News & Updates
Filter by Specialty:
Long-term hydrochlorothiazide use ups risk of skin cancer
17 Aug 2023
Using hydrochlorothiazide (HCTZ) for longer durations and in higher cumulative doses increases the risks for keratinocyte carcinoma and melanoma, reveals a study.
Long-term hydrochlorothiazide use ups risk of skin cancer
17 Aug 2023
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
byAudrey Abella
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
28 Jul 2023
byAudrey Abella
An integrated analysis of the pivotal phase IIb/III ALLEGRO and phase III ALLEGRO-LT studies demonstrated the long-term efficacy of the oral JAK3/TEC family kinase inhibitor ritlecitinib for alopecia areata (AA).
